Top

Hepatology International

Published in:

Open Access 02-03-2024 | Tenofovir | Letter to the Editor

Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

Authors: Yan Wang, Xiu Sun, Junyan Zhang, Qi Mei

Published in: Hepatology International | Issue 2/2024

Excerpt

Dear Editor …

https://training.cochrane.org/handbook/current/chapter-10#section-10-10.

https://link.springer.com/article/10.1007/s12072-023-10528-7#availability-of-data-and-materials.

https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fhepr.13726&file=hepr13726-sup-0001-suppl-data.pdf.

https://training.cochrane.org/handbook/archive/v6.3/chapter-08.

https://training.cochrane.org/handbook/current.

Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2023;17(4):860–869CrossRefPubMed

Borenstein M. In a meta-analysis, the I-squared statistic does not tell us how much the effect size varies. J Clin Epidemiol (United States). 2022;152:281–4.

Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (England). 2003;327(7414):557–560

Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet (England). 2002;359(9303):341–345CrossRef

Hosaka T, Suzuki F, Kobayashi M, et al. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res (Netherlands). 2022;52(2):153–64.

Title: Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Authors: Yan Wang
Xiu Sun
Junyan Zhang
Qi Mei
Publication date: 02-03-2024
Publisher: Springer India
Keywords: Tenofovir
Dyslipidemia
Hepatitis B
Published in: Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-024-10642-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2024

Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan

Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis

Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials